EGFR and non-small cell lung carcinoma: Non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers, and EGFR activating mutations are found in ~10–20% of advanced NSCLC cases in Europe and 30–50% of cases in East Asia [2–4].